Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

From India with H1N1 claims

This article was originally published in The Tan Sheet

Executive Summary

FDA warns an online firm based in India, 1www.ayurvediccure.com, it is marketing herbal products as unapproved drugs because they claim to prevent or treat the H1N1 flu virus. The agency's Jan. 26 warning letter says the noncompliant products include tinospora cordifolia, holy basil and ginger capsules. FDA has not approved the products to diagnose, mitigate, prevent, treat or cure H1N1, according to the letter posted on FDA's Web site April 7. The product claims on the firm's Web site included, "Regular uses of these medicines are helpful in controlling the signs and symptoms of deadly swine flu and help in early treatment of influenza." FDA says until the firm removes unapproved claims, it will include the firm's name in a list on the agency's Web site with other businesses that received warning letters about unapproved H1N1-related products

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS103992

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel